@article{49c939cdaf5d4fef921e7b1399fd12bb,
title = "Glucose responsive insulin production from human embryonic germ (EG) cell derivatives",
abstract = "Type 1 diabetes mellitus subjects millions to a daily burden of disease management, life threatening hypoglycemia and long-term complications such as retinopathy, nephropathy, heart disease, and stroke. Cell transplantation therapies providing a glucose-regulated supply of insulin have been implemented clinically, but are limited by safety, efficacy and supply considerations. Stem cells promise a plentiful and flexible source of cells for transplantation therapies. Here, we show that cells derived from human embryonic germ (EG) cells express markers of definitive endoderm, pancreatic and β-cell development, glucose sensing, and production of mature insulin. These cells integrate functions necessary for glucose responsive regulation of preproinsulin mRNA and expression of insulin C-peptide in vitro. Following transplantation into mice, cells become insulin and C-peptide immunoreactive and produce plasma C-peptide in response to glucose. These findings suggest that EG cell derivatives may eventually serve as a source of insulin producing cells for the treatment of diabetes.",
keywords = "Development, Diabetes, Endoderm, Pancreas, Stem, Transplantation",
author = "Clark, {Gregory O.} and Yochem, {Robert L.} and Joyce Axelman and Sheets, {Timothy P.} and Kaczorowski, {David J.} and Shamblott, {Michael J.}",
note = "Funding Information: Research funded by NIDDK Beta Cell Biology Consortium Pilot and Feasibility Study VU CA9182 (M.J.S.), JDRF Award 2-2002-306 (M.J.S.), National Stem Cell, Inc. Sponsored Research Award (M.J.S), NIH T32 DK007751 (G.O.C.), Diabetes Trust Foundation Clinical Scholars in Diabetes Fellowship (G.O.C.) and the C. Michael Armstrong Stem Cell Research Fellowship (G.O.C.). Islets were provided by the Islet Cell Resource Center. Some of the funding for the study described in this article was provided by National Stem Cell, Inc. Under a licensing agreement between National Stem Cell, Inc. and the Johns Hopkins University, Dr. Shamblott is entitled to a share of royalty received by the University on sales of products/technologies described in this article. Dr. Shamblott also is a paid consultant to National Stem Cell, Inc. The terms of this arrangement are being managed by the Johns Hopkins University in accordance with its conflict of interest policies. Under a licensing agreement between Geron Corporation and Johns Hopkins University, M.J.S. is entitled to a share of royalty received by the University on sales of products described in this presentation. M.J.S. and the University own Geron stock, which is subject to certain restrictions under University policy. The terms of this arrangement are being managed by the Johns Hopkins University in accordance with its conflict of interest policies. ",
year = "2007",
month = may,
day = "11",
doi = "10.1016/j.bbrc.2007.03.017",
language = "English (US)",
volume = "356",
pages = "587--593",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "3",
}